Dibromofluorescein disodium salt

CAS : 4372-02-5

Ref. 3D-FD44552

Informations sur le produit

• Nom: Dibromofluorescein disodium salt
• Synonymes: 4′,5′-Dibromofluorescein, Acid Orange 11, Bromo Acid Yellowish, D and C Orange No. 6, D+C Orange No. 6, Dibromofluorescein, Eosine 2J, Eosine S 10, Fluorescein, 4',5'-dibromo-, disodium salt (8CI), Fluorescein, 4′,5′-dibromo-, disodium salt, Fluorescein, 4′,5′-dibromo-, sodium deriv., sodium salt, Simacid Eosine YYS, Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 4′,5′-dibromo-3′,6′-dihydroxy-, disodium salt, Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 4′,5′-dibromo-3′,6′-dihydroxy-, sodium salt (1:2), disodium 4',5'-dibromo-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate

Description

Dibromofluorescein disodium salt (DBFDS) is a chemotherapeutic agent that is used in the treatment of eosinophil peroxidase-mediated diseases. This drug is also used as an optical sensor to measure the concentration of fatty acids in urine samples. The reaction mechanism of DBFDS involves the oxidation of the compound by hydrogen peroxide and a lipid substrate, which generates two reactive intermediates. The first intermediate reacts with oxygen to form a reactive radical species that reacts with another molecule of hydrogen peroxide to form an unstable compound, which then decomposes into bromine and fluorescein. The second intermediate reacts with magnesium salt to produce magnesium bromide and fluorescein. The intensity of fluorescence increases when the concentration of fatty acids increases. DBFDS has been shown to induce acute toxicities such as nausea, vomiting, headache, and diarrhea in humans, but this drug has not been shown to have carcin

• Marque: Biosynth

Propriétés chimiques

• Degré de pureté: Min. 95%